Economic and clinical burden associated with respiratory viral infections after allogeneic hematopoietic cell transplant in the United States.

ABSTRACT:

Background

Allogeneic hematopoietic cell transplant (allo-HCT) recipients are at increased risk for respiratory viral infections (RVIs), which invoke substantial morbidity and mortality. Limited effective antiviral options and drug resistance often hamper successful RVI treatment, creating additional burden for patients and the health care system.

Methods

Using an open-source health care claims database, we examined differences in clinical outcomes, health resource utilization, and total reimbursements during the 1-year period following allo-HCT in patients with and without any RVI infection (respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus). RVIs were diagnosed at any time ≤1 year after allo-HCT and identified by International Classific

SUBMITTER: Ison MG 

PROVIDER: S-EPMC9542538 | biostudies-literature | 2022 Aug

REPOSITORIES: biostudies-literature